Detalles de la búsqueda
1.
A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer.
Br J Cancer
; 130(3): 450-456, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38110665
2.
CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1/CTLA-4 bispecific antibody in patients with solid tumors.
Cancer Immunol Immunother
; 73(2): 36, 2024 Jan 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38280003
3.
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.
Lancet Oncol
; 24(10): 1134-1146, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37797632
4.
Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers.
Cancer Immunol Immunother
; 71(10): 2371-2379, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35165764
5.
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
J Immunother Cancer
; 12(4)2024 Apr 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38642937
6.
Preclinical imaging evaluation of a bispecific antibody targeting hPD1/CTLA4 using humanized mice.
Biomed Pharmacother
; 175: 116669, 2024 Apr 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38677243
7.
Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study.
Clin Cancer Res
; 30(8): 1501-1508, 2024 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38372727
8.
A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC.
J Thorac Oncol
; 19(3): 465-475, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37879536
9.
Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study.
Oral Oncol
; 151: 106723, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38387261
10.
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity.
MAbs
; 15(1): 2180794, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36872527
11.
Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study.
Dermatol Ther (Heidelb)
; 13(10): 2357-2373, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37668898
12.
Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study.
Dermatol Ther (Heidelb)
; 13(2): 555-567, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36566344
13.
A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study).
Lung Cancer
; 184: 107355, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37677918
14.
A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors.
Cell Rep Med
; 4(11): 101242, 2023 11 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37852261
15.
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial.
EClinicalMedicine
; 62: 102106, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37593227
16.
The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial.
Front Immunol
; 14: 1238667, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37942328
17.
Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed.
Biomark Res
; 10(1): 20, 2022 Apr 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35418166
18.
Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events.
Front Immunol
; 13: 924542, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35833116
19.
Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity.
J Immunother Cancer
; 10(11)2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36450383
20.
Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis.
Front Pharmacol
; 13: 966176, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36052126